Abstract
Nature Reviews Cancer 10, 9–22 (2010) On page 17 of this article, in the section Targeting αvβ3 and αvβ5 the sentence at the start of the second paragraph that reads “Cilengitide is an inhibitor of both αvβ3 and αvβ5 integrins, and it was selected in our laboratory by screening a library of cyclic RGD peptides in a cell-free receptor assay for their capacity to inhibit integrins αvβ3 and αvβ5 but not αΙΙbβ3 REF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.